Journal article icon

Journal article

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

Abstract:

Millions of HIV-infected people worldwide receive antiretroviral therapy (ART) in programmes using WHO-recommended standardised regimens. Recent WHO guidelines recommend a boosted protease inhibitor plus raltegravir as an alternative second-line combination. We assessed whether this treatment option offers any advantage over the standard protease inhibitor plus two nucleoside reverse-transcriptase inhibitors (NRTIs) second-line combination after 144 weeks of follow-up in typical programme set...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.1016/s1473-3099(17)30630-8

Authors


Expand authors...
Medical Research Council More from this funder
Swedish International Development Cooperation Agency More from this funder
Expand funders...
Publisher:
Elsevier Publisher's website
Journal:
Lancet: Infectious Diseases Journal website
Volume:
18
Issue:
1
Pages:
47-57
Publication date:
2017-11-03
Acceptance date:
2017-10-15
DOI:
EISSN:
1474-4457
ISSN:
1473-3099
Pubs id:
pubs:747436
URN:
uri:2e01ee42-16a3-48ab-bdec-8198eeb47a05
UUID:
uuid:2e01ee42-16a3-48ab-bdec-8198eeb47a05
Local pid:
pubs:747436
Paper number:
1

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP